Axsome Therapeutics (AXSM) Equity Average (2016 - 2026)

Axsome Therapeutics' Equity Average history runs 11 years deep, the most recent figure standing at $71.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 29.63% year-over-year to $71.4 million; the TTM figure through Mar 2026 stood at $71.4 million (up 29.63% YoY), while the FY2025 annual figure was $72.7 million, down 41.41% from the prior year.
• Equity Average came in at $71.4 million for Q1 2026 at Axsome Therapeutics, down from $81.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $274.2 million in Q3 2023 to a low of $14.9 million in Q2 2022.
• A 5-year average of $109.9 million and a median of $86.3 million in 2022 frame the typical range for Equity Average.
• Across the five-year window, Equity Average sank 85.56% in 2022 and soared 1206.54% in 2023, its largest moves.
• Axsome Therapeutics' Equity Average stood at $133.5 million in 2022, then surged by 72.52% to $230.2 million in 2023, then plunged by 67.44% to $75.0 million in 2024, then rose by 8.08% to $81.0 million in 2025, then declined by 11.81% to $71.4 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $71.4 million, $81.0 million, and $73.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison